South Dakota Investment Council Eagle Pharmaceuticals, Inc. Transaction History

South Dakota Investment Council

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$25.06 - $34.09 $22,228 - $30,237	887 Added 3.33%	27,562 $782,000
Q4 2022 Feb 07, 2023	BUY	$24.98 - $39.77 $129,896 - $206,804	5,200 Added 24.21%	26,675 $780,000
Q2 2022 Aug 11, 2022	SELL	$41.26 - $51.35 $2.89 Million - $3.6 Million	-70,059 Reduced 76.54%	21,475 $954,000
Q1 2022 May 10, 2022	SELL	$44.58 - $52.6 $936,180 - $1.1 Million	-21,000 Reduced 18.66%	91,534 $4.53 Million
Q4 2021 Feb 08, 2022	BUY	$45.82 - $56.9 $134,252 - $166,717	2,930 Added 2.67%	112,534 $5.73 Million
Q3 2021 Nov 09, 2021	BUY	$43.79 - $55.78 $2.37 Million - $3.01 Million	54,010 Added 97.15%	109,604 $6.11 Million
Q2 2021 Aug 11, 2021	BUY	$36.86 - $44.5 $2.05 Million - $2.47 Million	55,594 New	55,594 $2.38 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of South Dakota Investment Council, based on Form 13F filings with the SEC.

Stay updated on South Dakota Investment Council with notifications on news.